|
 |
| home > epc > autumn 2003 > visualisation in drug discovery: the way of the future |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
A geographically dispersed drug discovery team whose members are based in Oslo, Toronto and London analyse unimaginably large molecular model data together, at the same time, by visualising virtual molecules in 3D whilst in different offices. As they work, the team is able to make changes to the 3D data in real-time helping them reach a collaborative decision quickly. They are working under enormous pressure to develop an urgently needed new drug and the visualisation technology allows them to reach a marketable cure in record time. World experts can work together easily even though they are based hundreds of thousands of miles apart. Welcome to drug discovery supported by visual area networking.
The entire pharmaceutical discovery process is on the cusp of a visualisation technology revolution involving not only the transformation of large data sets into 3D and even 4D graphical form, but also the real-time manipulation of those images by internationally distributed teams for greatly enhanced decision-making on user-friendly, uncomplicated platforms.
The field of drug discovery has progressed enormously over the past few decades and ground-breaking advances have been made, from the discovery of new anti-infectives to medications that slow the progress of HIV. However more impressive advances are yet to come, with high-performance computing (HPC) paving the way for an even more efficient approach to drug discovery. Supercomputing, visualisation and data storage technologies are dramatically reducing the time it takes to discover new drugs, with the process of drug discovery becoming much more efficient and allowing scientists to collaborate more easily.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Vindon Scientific on the Move
More info >> |
|
 |
